Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 22, 2017
Pharmacy Choice - Pharmaceutical News - Analyst Activity BTIG Research Initiates Coverage On Axsome Therapeutics (NASDAQ:AXSM) With a Buy - September 22, 2017

Pharmacy News Article

 5/19/17 - Analyst Activity BTIG Research Initiates Coverage On Axsome Therapeutics (NASDAQ:AXSM) With a Buy

Analyst Ratings For Axsome Therapeutics (NASDAQ:AXSM)

Today, BTIG Research initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy with a price target of $14.00.

There are 4 buy ratings on the stock.

The current consensus rating on Axsome Therapeutics (NASDAQ:AXSM) is Buy (Score: 3.00) with a consensus target price of $15.67 per share, a potential 312.28% upside.

Some recent analyst ratings include

  • 5/19/2017-BTIG Research initiated coverage with a Buy rating.
  • 3/21/2017-Aegis Reiterated Rating of Buy.
  • 10/3/2016-Brean Capital initiated coverage with a Buy rating.

Dividend information for Axsome Therapeutics (NASDAQ:AXSM)

Recent Insider Trading Activity For Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM) has insider ownership of 42.30% and institutional ownership of 33.07%.

  • On 12/23/2015 Randall Kaye, Insider, bought 1,000 with an average share price of $9.03 per share and the total transaction amounting to $9,030.00. View SEC Filing

About Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Recent Trading Activity for Axsome Therapeutics (NASDAQ:AXSM)
Shares of Axsome Therapeutics closed the previous trading session at 3.80 0.00 0.00% with 198,736 shares trading hands.

The post Analyst Activity BTIG Research Initiates Coverage On Axsome Therapeutics (NASDAQ:AXSM) With a Buy appeared first on Market Exclusive.

© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Sep 22: Influenza 2017-2018: An Update on Prevention and Treatment
Sep 24: Using Effective Communication to Reduce Medication Errors
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Sep 27: Medication Use During Pregnancy & Lactation
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement